GlassScriptPhysician profile
Jose Ignacio Lopez
NPI 1942307681
$2,050.30
in general payments reported to CMS, 2019-2025
19 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $189 · 2021: $259 · 2022: $62.73 · 2023: $350 · 2024: $195 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $776.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $501.54 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $251.31 | 2019-2025 | Farxiga, Airsupra |
| Cook Medical LLC | $238.02 | 2023 | Zenith Spiral-Z, Zilver Ptx |
| Amarin Pharma, INC. | $154.15 | 2021 | |
| Novo Nordisk INC | $129.82 | 2024-2025 | Ozempic, Rybelsus |
| Tetraphase Pharmaceuticals, INC. | $119.68 | 2019 | |
| Pfizer INC. | $116.93 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.08 | 2019-2025 | Jardiance |
| Abbvie INC. | $70.39 | 2021-2023 | |
| Glaxosmithkline, LLC. | $69.12 | 2020-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $65.91 | 2019-2020 | |
| Amgen INC. | $60.70 | 2019-2025 | Repatha, Otezla |
| Lilly USA, LLC | $40.86 | 2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $29.08 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $25.54 | 2025 | Zoryve |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $24.07 | 2019 | |
| Abbott Laboratories | $18.42 | 2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $18.08 | 2022 | |
| Sumitomo Pharma America, INC. | $14.60 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.